The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanismMary Ann Anderson, Andrew W. Roberts, Lijian Yu et al.|Blood|2016Cited by 329
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicityBenjamin L. Lampson, Jennifer R. Brown, Siddha Kasar et al.|Blood|2016Cited by 289
Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemiaBenjamin L. Lampson, Jennifer R. Brown, Haesook T. Kim et al.|Blood Advances|2019Cited by 29